GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors
"A seasoned biopharmaceutical industry executive with years of
experience in financial and leadership roles, Daniel is a great addition
to the GlycoMimetics Board of Directors," said
"There remain so many critical unmet needs in the treatment of
individuals living with various cancers," said
About
GlycoMimetics's wholly-owned drug candidate (GMI-1271) for AML and other
blood disorders is also in clinical trials.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160321005547/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media